🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Novartis showcases new results in newly diagnosed chronic myeloid leukemia at #ASH24 and late-breaking analysis in early breast cancer at #SABCS. go.novartis.social/3Oqugmc #NovartisNews #ReimaginingMedicine

Novartis announces European Commission approval for its CDK4/6 inhibitor in a broad population of stage II or III HR+/HER2- #earlybreastcancer patients, including those with node-negative disease at high risk of recurrence. go.novartis.social/4fFzzdA #NovartisNews

Following the FDA approval of our treatment for newly diagnosed adults with chronic myeloid leukemia (CML) and category 1 recommendation in National Comprehensive Cancer Network (NCCN) guidelines, we will present longer-term data from our Phase III ASC4FIRST trial at ASH. #NovartisNews #ASH24

Longer-term Novartis NATALEE data shows risk of distant recurrence continues to decrease in broad population of patients with #earlybreastcancer. Read More: go.novartis.social/4imHgax #NovartisNews #ReimaginingMedicine

Data from the Phase III STEER study demonstrate clinically meaningful results in patients with #spinalmuscularatrophy aged two to 18 years. Read more: go.novartis.social/41XEbHZ #NovartisNews

Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024. go.novartis.social/3WEy3Rm #NovartisNews $NVS $NOVN #NVSQ424

#NVSQ424 Novartis social media posts on Q4 and Full-Year 2024 contain non-IFRS measures. An explanation of non-IFRS measures is available on our website: go.novartis.social/3Eij89f $NVS $NOVN #NovartisNews

Novartis announces positive CHMP opinion for adult C3 glomerulopathy treatment (#C3G) #NovartisNews #ReimaginingMedicine go.novartis.social/4iit6q2

Novartis highlights commitment to hidradenitis suppurativa and chronic spontaneous urticaria at AAAAI and AAD annual congresses #NovartisNews go.novartis.social/3DkTQak

Results from the Phase III STEER and Phase IIIb STRENGTH studies are being presented this week at the MDA Conference. Learn about the latest advancements in gene replacement therapy for #SpinalMuscularAtrophy: go.novartis.social/4iYLMv9 #NovartisNews

Novartis announces first-ever FDA approval in ultra-rare #kidneydisease #C3G #NovartisNews go.novartis.social/41HOnTj

Novartis to share 7-year data in relapsing #multiplesclerosis and additional studies across neuroscience portfolio at #AANAM in San Diego. Learn more: go.novartis.social/4hJ0i9u #NovartisNews

Novartis announces FDA approval of radioligand therapy for earlier use before chemotherapy in PSMA-positive metastatic prostate cancer (mCRPC) go.novartis.social/4hMHSEF #NovartisNews

Novartis announces FDA accelerated approval of treatment to reduce proteinuria in primary IgA nephropathy (#IgAN) go.novartis.social/4jkd1kb

Novartis announces Q1 2025 earnings. Learn more in our press release: go.novartis.social/4juRB46 #NovartisNews $NVS $NOVN #NVSQ12025

#NVSQ12025 Novartis social media posts on Q1 2025 contain non-IFRS measures. An explanation of non-IFRS measures is available on our website. go.novartis.social/3Yof2no $NVS $NOVN #NovartisNews

#NVSQ12025 Novartis social media posts on Q1 2025 earnings contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. go.novartis.social/4iD25gu $NVS $NOVN

Novartis has agreed to acquire Regulus Therapeutics, a clinical-stage biopharmaceutical company focused on developing microRNA therapeutics with a focus on autosomal dominant polycystic kidney disease (ADPKD), a severe renal disease. For more information and cautionary

#News: We’re excited to announce our upcoming oncology and hematology data that has been recently accepted at ASCO Annual Meeting and @eha_hematology 2025 Congress. #ASCO25 #EHA2025. go.novartis.social/4j9waoq